Chemotherapy of acute myeloblastic leukaemia with DAM regimen
Yunus, A.B.; Sayeed, M.A.; Barua, A.; Rahman, J.; Rashid, M.A.
Bangladesh Medical Research Council Bulletin 23(3): 82-86
1997
ISSN/ISBN: 0377-9238 PMID: 9621477 Document Number: 470380
32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6-Mercaptopurine (DAM) regimen. Remission induction was instituted with 1-3 cycles of DAM regimen and maintenance was given by 6-MP continuously with intermittent DA (1,5) regimen. In the remission induction, Doxorubicin 30 mg/m2 for 3 days, Ara-C 150 mg/m2 for 5 days and 6-Mp 100 mg/m2 daily was given. Complete remission (CR) was observed in 60% cases. The probability of 2 years disease-free survival of patients with complete remission is 56.73%.